$111.34
▲ +0.3% Today
as of Aug 5, 16:51 ET
Last 30 days
Recent Press Releases & News
Veradermics (MANE) Positioned to Disrupt Hair Loss Market
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Overview
52-week range
$32
$118
93% of range
Avg surprise (last 1)
-135.7%
Avg reaction (last 1)
-3.9%
0% positive
Latest IV / EM
97%
EM ±16.1% · $110 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-1.32 | $-0.56 | -135.7% | — | -3.9% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-19.79 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.58 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-30M | — | $-13M |
| Net income | $-27M | — | $-12M |
| EPS (diluted) | $-1.32 | — | $-19.79 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $168M | $22M | — |
| Inventory | — | — | — |
| Total current assets | $397M | $152M | — |
| Total assets | $397M | $153M | — |
| Long-term debt | — | — | — |
| Total liabilities | $7M | $9M | — |
| Total equity | $391M | $-121M | $-61M |